4.8 Review

Aptamers in the Therapeutics and Diagnostics Pipelines

Journal

THERANOSTICS
Volume 8, Issue 15, Pages 4016-4032

Publisher

IVYSPRING INT PUBL
DOI: 10.7150/thno.25958

Keywords

aptamers; therapeutics; diagnostics; clinical trials; clinical diagnostics

Funding

  1. Department of Biotechnology, Govt. of India for DBT-Innovative Young Biotechnologist Award
  2. Translational Health Science and Technology Institute (THSTI)

Ask authors/readers for more resources

Aptamers are short single-stranded DNA or RNA oligonucleotides that can selectively bind to small molecular ligands or protein targets with high affinity and specificity, by acquiring unique three-dimensional structures. Aptamers have the advantage of being highly specific, relatively small in size, non-immunogenic and can be easily stabilized by chemical modifications, thus allowing expansion of their diagnostic and therapeutic potential. Since the invention of aptamers in the early 1990s, great efforts have been made to make them clinically relevant for diseases like macular degeneration, cancer, thrombosis and inflammatory diseases. Furthermore, owing to the aforementioned advantages and unique adaptability of aptamers to point-of-care platforms, aptamer technology has created a stable niche in the field of in vitro diagnostics by enhancing the speed and accuracy of diagnoses. The aim of this review is to give an overview on aptamers, highlight the inherent therapeutic and diagnostic opportunities and challenges associated with them and present various aptamers that have reached therapeutic clinical trials, diagnostic markets or that have immediate translational potential for therapeutics and diagnostics applications.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available